A Colorado man recently tested positive for a highly contagious strain of Avian Flu that has likely killed hundreds of birds.
The inmate was the first person in the United States to test positive for bird flu as an ongoing outbreak in the country continues to affect birds and poultry.
Full statement: Colorado reports human case of H5N1 bird flu, the first in the U.S. pic.twitter.com/3bRPr6ob2u
— BNO News (@BNONews) April 29, 2022
1st case of H5N1 avian/bird flu spillover to a person in the US (out of 2,500 tracked by CDC), 2nd globally. CDC says human spillover risk is low, but infections in captive birds in 29 states and wild birds in 34 states, concerns abound #PreventPandemics https://t.co/Wq85XyuyZZ
— Tanya Sanerib (@ts4biodiversity) April 29, 2022
While the CDC reportedly said the risk the virus poses to people remains low, a recently discovered piece of information has raised my eyebrows.
An old article revealed the U.S. government applied for a patent for a new vaccine against influenza, particularly for bird flu (H5N1).
“The vaccine incorporates genes from a H5N1 strain isolated from an Indonesian human victim of bird flu in 2005,” according to a 2008 GRAIN article.
The patent application, first published as application WO2007/100584 on 7 September 2007 on a WIPO internet database, is for a new type called a “DNA vaccine.”
Ladies & Gents, I think we have what is going to be the New Pandemic. First case already noted last Thursday. 🧬 DNA 💉. I wonder how many will fall for this one. My best friend DUG. We do our research. What are YOUR thoughts? 🚨😳🙏 pic.twitter.com/5CtqKtbMKL
— 🌸🧚🏽♀️Truth Fairy🧚🏽♀️🌸 (@TruthFairy27169) May 2, 2022
The strain that contains the genes was transferred to the WHO GISN by Indonesia for characterization for public health purposes, but may wind up as the property of the US government.
Under US law, the US government agencies would offer licenses to the technology to pharmaceutical companies. The patent application indicates that the US government intends to pursue the claim in most countries of the world, including Indonesia itself, as well as neighboring countries.
The application was first lodged in the United States on 16 February 2006, and then filed with the World Intellectual Property Organization (WIPO) on 16 February 2007. It was first published as application WO2007/100584 on 7 September 2007 on a WIPO internet database, but is only now coming into public light.
The patent application claims a new vaccine against influenza, particularly for Bird Flu (H5N1). The vaccines incorporate one to four genes from a H5N1 strain isolated from an Indonesian human victim in 2005 (denominated A/Indonesia/5/05).
The patent application also claims similar vaccines that incorporate genes of flu strains from Thailand (A/Thailand/1(KAN-1)/04) and A/Ck/Thailand/1/04), Hong Kong (A/Hong Kong/156/97) and South Korea (A/Ck/Korea/ES/03).
The vaccine is of a new type called a DNA vaccine. These stimulate the immune system like others vaccines, except instead of using a traditional approach, such as injecting a dead virus, they consist of lengths of genetically engineered DNA called plasmids. This type of vaccine is under development in a number of biotech labs.
A new type of injection, called a ‘DNA vaccine,’ has been in the works for over a decade.
And it will consist of genetically engineered DNA.
What happened last time with a ‘vaccine’ containing experimental technology?
The catastrophic COVID-19 shots!
After the global rollout of mRNA gene therapy injections, bird flu cases are surfacing again.
Here’s what the WHO says about ‘DNA vaccines’:
Recently, a radically new approach to vaccination has been developed. It involves the direct introduction into appropriate tissues of a plasmid containing the DNA sequence encoding the antigen(s) against which an immune response is sought, and relies on the in situ production of the target antigen. This approach offers a number of potential advantages over traditional approaches, including the stimulation of both B- and T-cell responses, improved vaccine stability, the absence of any infectious agent and the relative ease of large-scale manufacture. As proof of the principle of DNA vaccination, immune responses in animals have been obtained using genes from a variety of infectious agents, including influenza virus, hepatitis B virus, human immunodeficiency virus, rabies virus, lymphocytic chorio-meningitis virus, malarial parasites and mycoplasmas. In some cases, protection from disease in animals has also been obtained. However, the value and advantages of DNA vaccines must be assessed on a case-by-case basis and their applicability will depend on the nature of the agent being immunized against, the nature of the antigen and the type of immune response required for protection.
The field of DNA vaccination is developing rapidly. Vaccines currently being developed use not only DNA, but also include adjuncts that assist DNA to enter cells, target it towards specific cells, or that may act as adjuvants in stimulating or directing the immune response. Ultimately, the distinction between a sophisticated DNA vaccine and a simple viral vector may not be clear. Many aspects of the immune response generated by DNA vaccines are not understood. However, this has not impeded significant progress towards the use of this type of vaccine in humans, and clinical trials have begun.
The first such vaccines licensed for marketing are likely to use plasmid DNA derived from bacterial cells. In future, others may use RNA or may use complexes of nucleic acid molecules and other entities. These guidelines address the production and control of vaccines based on plasmid DNA intended for use in humans.
Could something sinister be at play with the latest reports of bird flu?
While I think it’s too early to tell for sure, this patent for a ‘DNA vaccine’ is highly suspect.
Here’s Patent WO/2007/100584 on the WIPO IP Portal:
These vaccines target H5N1, H1, H3 and other subtypes of influenza and are designed to elicit neutralizing antibodies, as well as cellular immunity. The DNA vaccines express hemagglutinin (HA) or nucleoprotein (NP) proteins from influenza which are codon optimized and/or contain modifications to protease cleavage sites of HA which affect the normal function of the protein. Adenoviral constructs expressing the same inserts have been engineered for prime boost strategies. Protein-based vaccines based on protein production from insect or mammalian cells using foldon trimerization stabilization domains with or without cleavage sites to assist in purification of such proteins have been developed. Another embodiment of this invention is the work with HA pseudotyped lentiviral vectors which would be used to screen for neutralizing antibodies in patients and to screen for diagnostic and therapeutic antivirals such as monoclonal antibodies.